Asgard Therapeutics names Wolfram Brugger as chief medical officer to lead clinical transition
Source: SeekingAlpha
2026-04-14 06:07:58 ET
More on Autolus Therapeutics
- Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
- Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights - Slideshow
- Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
- Autolus reiterates $120M–$135M AUCATZYL revenue target for 2026 while expanding pivotal trial pipeline
- Autolus Therapeutics FY 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Asgard Therapeutics names Wolfram Brugger as chief medical officer to lead clinical transition
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
20.32% G/L:
$1.895 Last:
1,717,980 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
